Published • loading... • Updated
Real-World Study Finds Lower Weight Loss with GLP-1 Drugs Due to Early Discontinuation
- Researchers from Cleveland Clinic published a June 10, 2025 study showing semaglutide and tirzepatide caused smaller weight loss in adults treated for obesity in real-world U.S. settings.
- The differences from clinical trials were due to patients stopping their treatment more frequently and receiving reduced maintenance doses in routine clinical settings.
- Among 7,881 patients treated between 2021 and 2023, more than 20% discontinued their medication within the first three months and 32% stopped between three months and one year; those who remained on treatment for the full year experienced an average body weight reduction of 11.9%.
- Dr. Hamlet Gasoyan emphasized that insights gained from how these drugs are utilized in everyday clinical practice, along with the related patient outcomes, can guide healthcare providers and patients in making informed choices about when to stop treatment and how to manage maintenance dosing for effective weight loss.
- The study highlighted that treatment discontinuation also harmed blood sugar control in prediabetic patients, emphasizing the need for persistence to achieve clinical benefits.
Insights by Ground AI
Podcasts & Opinions
18 Articles
18 Articles
Evening StandardReposted by 
perspectivemedia.com
perspectivemedia.comWeight loss jabs could be transformative, says outgoing NHS England official
An estimated 1.5 million people are taking weight loss jabs in the UK.
·London, United Kingdom
Read Full Article
Weight loss injections might have lesser impact in real world compared to trials, finds study
A new study published in the Obesity Journal found that anti-obesity injections may have a lesser impact on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose. Read on to know more.
·India
Read Full Article
Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation
A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages.
·United States
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left3Leaning Right3Center3Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
